Atherosclerosis is driven by cardiovascular risk factors that cause the recruitment of circulating immune cells beneath the vascular endothelium. Infiltrated monocytes differentiate into different macrophage subtypes with protective or pathogenic activities in vascular lesions. We discuss current knowledge about the molecular mechanisms that regulate lesional macrophage proliferation and apoptosis, two processes that occur during atherosclerosis development and regulate the number and function of macrophages within the atherosclerotic plaque.
INTRODUCTION
Atherosclerosis and associated cardiovascular disease (myocardial infarction and stroke) are the leading causes of mortality and morbidity in developed countries, and projections of global mortality and disease burden predict that by 2020-2030 these disorders will be the main cause of death worldwide [1] [2] [3] . Cardiovascular risk factors (e.g. dyslipidemia, hypertension, diabetes and smoking) instigate a chronic inflammatory response that causes endothelial dysfunction, a key process in the initiation and progression of atherosclerosis. Dysfunctional endothelial cells trigger the recruitment of circulating leukocytes to the subendothelial space [4, 5] . Infiltrated monocytes differentiate into macrophages and dendritic cells, which are essential mediators of the local immune response underlying the accumulation of lipids, cells and extracellular matrix components in the injured vessel wall [6 && ]. During the first steps of atherosclerosis, intimal macrophages and dendritic-like cells phagocytose matrix-retained oxidized low-density lipoproteins (oxLDLs) through scavenger receptors and become foam cells, the main components of the 'fatty streak'. The prolonged accumulation of lipidderived apoptotic cells, cell debris and cholesterol crystals leads to the formation of the necrotic core, a hallmark of advanced atherosclerotic plaques.
Lesional macrophages acquire specialized phenotypes in response to signals from the local microenvironment that polarize them towards a specific activation state [7 atherosclerotic plaque has attracted much interest in the light of evidence that distinct macrophage subtypes, with different protective or pathogenic functions, predominate at different stages of atherosclerosis [6 && ,8,9] . Accumulation of alternatively activated macrophages (M2 or AAMs) in early lesions might be a mechanism to limit disease progression in the initial phases, whereas increased polarization towards proinflammatory classically activated macrophages (M1 or CAMs) is thought to perhaps contribute to the expansion and vulnerability of advanced plaques. M2 macrophages support a number of key anti-inflammatory activities that limit atherosclerosis progression, including inhibition of immune cell recruitment through transforming growth factor b production, IL-10-dependent reduction of IFNg synthesis, and clearance of apoptotic cells and tissue debris, a process known as efferocytosis [10] [11] [12] . In advanced phases of the disease, however, secretion of metalloproteinases, a characteristic of M2-like macrophages, contributes to matrix degradation and the formation of unstable plaques, which can rupture and trigger life-threatening myocardial infarction or stroke.
Key factors controlling neointimal macrophage accumulation -and consequently plaque growth and vulnerability -include monocyte infiltration, intimal macrophage proliferation and apoptosis, and monocyte/macrophage egress from the lesion to the bloodstream. Although recruitment from the blood has traditionally been considered the main route by which immune cells reach inflamed tissues [7 && ], recent studies suggest that tissue-resident macrophages can expand rapidly in situ during T-helper 2 (Th2)-dependent inflammation [13 && ], which is a key process in atherosclerosis [5] . This review discusses recent knowledge about the mechanisms that control macrophage proliferation and apoptosis in the atherosclerotic plaque.
MACROPHAGE PROLIFERATION AND ATHEROSCLEROSIS
Studies in human atherosclerotic plaques have detected expression of proliferation markers in intimal macrophages, which may be the predominant proliferative cell type in the atherosclerotic plaque [14, 15] . Expression of positive cell cycle regulators has also been detected in macrophages in the restenotic lesions of patients with peripheral artery disease, although these accounted for only a small proportion of proliferating cells compared with vascular smooth muscle cells (VSMCs) [16] . Cell proliferation is also evident in macrophages within atherosclerotic plaques from dyslipidemic rabbits and mice [17] [18] [19] [20] [21] . This section discusses evidence from mouse models and human studies for the roles of tumor-suppressor genes, myeloid growth factors and oxLDLs in macrophage proliferation and atherosclerotic lesion growth ( Fig. 1 ).
Tumor-suppressor genes in macrophage proliferation and atherosclerosis
The importance of lesional macrophage proliferation in atherosclerosis development has been investigated in genetically modified mice lacking tumor-suppressor genes expressed in animal and human atherosclerotic lesions [22] (Table 1) . Systemic and hematopoietic-restricted inactivation of p27 Kip1 increases intimal macrophage proliferation and accelerates atherosclerosis in apolipoprotein E-null (apoE-KO) mice [19, 20] . Similarly, macrophage-specific deficiency for retinoblastoma protein (RB) in apoE-KO mice increases lesional macrophage proliferation and enhances atherosclerosis development without affecting apoptosis [23] . Systemic inactivation of the growth suppressor and pro-apoptotic protein p53 in apoE-KO mice also increases intimal cell proliferation and enhances atherosclerosis [21, 24] . However, studies using different mouse strains and strategies to manipulate KEY POINTS Accumulation of macrophages in atherosclerotic lesions is regulated by the equilibrium between proliferation and apoptosis.
In early lesions, macrophages appear to limit disease progression through rapid clearance of apoptotic cells (efferocytosis); however, as disease progresses, defective efferocytosis and the ensuing accumulation of apoptotic cells promote plaque inflammation, necrosis and instability.
Preclinical studies show that lesional macrophage accumulation and atherosclerosis burden are modulated by macrophage-specific manipulation of genes involved in cell proliferation and apoptosis and by treatment with myeloid-specific growth factors.
Endoplasmic reticulum stress (ERS) has emerged as a key effector of macrophage apoptosis, and recent studies have begun to elucidate the mechanisms that induce ERS in the plaque and the ensuing apoptotic response.
Despite the recent advances in our understanding of how intimal macrophage proliferation and apoptosis are regulated in atherosclerotic lesions, additional work is needed to translate this knowledge into new therapies to combat atherothrombosis.
p53 expression in macrophages have yielded conflicting results. Atherosclerosis was increased in lethally irradiated apoEÃ3-Leiden transgenic mice reconstituted with p53-null bone marrow, correlating with increased lesional macrophage content and a tendency towards decreased apoptosis without affecting proliferation [25] . Atherosclerosis was also increased upon transfer of p53-null bone marrow cells into LDL receptor-null (Ldlr-KO) mice; however, immunohistopathological analysis revealed increased intimal cell proliferation and vulnerable-appearing lesions marked by augmented tissue necrosis and reduced collagen deposition, without effects on apoptosis [26] . In contrast with these findings, macrophage-specific p53 inactivation using the Cre-loxP system did not affect atherosclerosis burden in apoE-KO mice, despite an increased lesional macrophage content that coincided with reduced macrophage apoptosis, unaltered proliferation and reduced accumulation of cholesterol in the lesion [27] . Transplantation of p53 bone marrow to mice lacking p53 and apoE reduced intimal cell proliferation and apoptosis and plaque formation [21] ; but in another gain-of-function approach, Super-p53/apoE-KO mice, which have an extra copy p53, showed no changes in intimal cell proliferation, apoptosis or atherosclerosis burden [28] .
Similar confusion surrounds the role in atherosclerosis of the tumor suppressor p21 Cip1 , a downstream target of p53. Merched and Chan [29] reported that whole-organism or bone marrowrestricted deletion of p21 Cip1 protects against atherosclerosis in apoE-KO mice. Plaques in mice lacking both p21 Cip1 and apoE are more stable than plaques in mice lacking only apoE, with increased apoptosis but unaltered cellular proliferation. Interestingly, p21 Cip1 -null macrophages also show increased phagocytic activity towards latex microspheres and apoptotic cells, suggesting that p21 Cip1 promotes atherogenesis in part by impeding this phagocytotic activity. In marked contrast, however, Akyurek et al. [30] found accelerated atherogenesis in apoE-KO mice systemically deficient for p21 Cip1 , consistent with the growth suppressive role of this protein.
Atherosclerosis risk in humans has been associated with several single-nucleotide polymorphisms (SNPs) in a region of chromosome 9p21 near the Ink4/Arf locus. This locus includes the growthsuppressor genes CDKN2A (encoding p16 Ink4a and ARF: human p14 Arf , mouse p19 Arf ) and CDKN2B (encoding p15 Ink4b ), and the antisense noncoding RNA ANRIL, which silences Ink4/Arf expression [42] . Interestingly, some studies have demonstrated correlations between the 9p21 risk-associated SNPs and expression of ANRIL and Ink4/Arf in circulating leukocytes [42] , suggesting a role for Ink4/Arf growth suppressors in the identified genetic association. However, Holdt et al. [43 & ] found no clear association between 9p21 genotype and CDKN2A and CDKN2B expression in human atherosclerotic plaques. Recent mouse studies have investigated the role of the Ink4/Arf growth suppressors in atherosclerosis ( [21] apoE-KO p53 global inactivation Increased intimal cell proliferation Increase [24] apoEÃ3-Leiden p53À/À BMT in p53þ/þ mice None Increase [25] Ldlr-KO p53À/À BMT in p53þ/þ mice Increased macrophage proliferation Increase [26] apoE-KO Macrophage-specific p53 deficiency None None [27] apoE-KO p53þ/þ BMT in p53À/À mice Reduced macrophage proliferation (brachiocephalic)
Reduction (aorta) None (brachiocephalic) [21] apoE-KO One extra p53 allele (normally regulated) None None [28] apoE-KO p21 Cip1 global inactivation None Reduction [29] apoE-KO p21 Cip1 À/À BMT in p21 Cip1 þ/þ mice Not reported Reduction [29] apoE-KO Ldlr-KO GM-CSF treatment Increased intimal cell proliferation Not reported [37] Ldlr-KO Antibody anti-GM-CSF treatment Reduced intimal cell proliferation Not reported [37] Ldlr-KO GM-CSF global inactivation Reduced intimal dendritic cell proliferation Reduction [38] apoE-KO GM-CSF global inactivation Increased macrophage plaque content Increase [39] apoE-KO GM-CSF treatment Not reported Increase [40] Ldlr-KO Hiperlipidemia and hyperglycemia treatment Increased macrophage proliferation Increase [41] BMT, bone marrow transplant; GM-CSF, granulocyte/macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor, RB, retinoblastoma.
inflammatory signaling in mouse macrophages [44] , transplantation of p16 Ink4a -null bone marrow into Ldlr-KO mice does not affect atherosclerosis [33 & ].
Myeloid growth factors and oxidized lowdensity lipoprotein in macrophage proliferation and atherosclerosis
Macrophage and granulocyte/macrophage colonystimulating factors (M-CSF and GM-CSF) are key regulators of myeloid cell proliferation and survival during homeostasis and inflammation [45] . M-CSF expression is elevated in atherosclerotic lesions in rabbits and pigs [46, 47] and in the plasma of patients with angina pectoris [48] . Moreover, M-CSF release and macrophage proliferation are induced by C-reactive protein [49] , a biomarker of inflammation and a predictor of future risk of cardiovascular disease [50] . Notably, M-CSF deficiency inhibits atherogenesis in apoE-KO mice [34, 35] , and treatment of mice with M-CSF after wiremediated femoral artery denudation accelerates the formation of neointimal lesions, which mostly consist of bone marrow-derived cells [36] . However, in hypercholesterolemic rabbits, M-CSF treatment reduces cholesterol ester accumulation in the aorta and prevents atherosclerosis [51, 52] ( Table 1 ). The role of GM-CSF in atherosclerosis is less clear. Systemic injection of GM-CSF in Ldlr-KO mice markedly increases cell proliferation in nascent atherosclerotic lesions and proliferation is inhibited by function-blocking anti-GM-CSF antibody [37] . More than 90% of the proliferating intimal cells in Ldlr-KO mice are dendritic cells [37] , and GM-CSF deficiency in this model reduces the content of intimal dendritic cells and causes a 20-50% decrease in atheroma size, depending on the location of the lesions [38] . Whereas these results suggest a proatherogenic role of GM-CSF in Ldlr-KO mice, studies in apoE-KO mice showed accelerated atherosclerosis by both GM-CSF genetic disruption [39] and treatment with GM-CSF [40] . Finally, studies in hyperlipidemic rabbits showed reduced atherosclerosis upon GM-CSF treatment [53] . The use of different animal models and approaches to manipulate GM-CSF expression and function might explain these seemingly conflicting findings.
Hypercholesterolemia results in the accumulation of oxLDL in the arterial wall, and its internalization by macrophages in the atherosclerotic plaque converts these cells into foam cells [6 && ]. oxLDL can induce macrophage proliferation, a process inhibited by statins in vitro and in vascular lesions in vivo [54] [55] [56] [57] . GM-CSF plays an essential role in oxLDL-induced macrophage proliferation [58] [59] [60] , with both protein kinase C (PKC) [61, 62] and extracellular signal-regulated kinase (ERK) [63] being involved in oxLDL-dependent GM-CSF production. In contrast, GM-SCF production and macrophage proliferation are inhibited by adenosine monophosphate-activated protein kinase (AMPK), through increases in the levels of p53, p21 Cip1 and p27 Kip1 , and a decrease in RB phosphorylation [64] . Interestingly, a combination of hyperglycemia and hyperlipidemia in Ldlr-KO mice stimulates macrophage proliferation in atherosclerotic lesions via a pathway that may involve glucosedependent LDL oxidation [41] .
MACROPHAGE APOPTOSIS AND ATHEROSCLEROSIS
Macrophage apoptosis has been identified as a prominent feature of atherosclerotic plaques at all stages of the disease. In early atherosclerosis, rapid efferocytosis by intimal phagocytes (mainly M2 macrophages) reduces the accumulation of apoptotic cells and thus limits local inflammation and lesion growth by preventing secondary cellular necrosis [65, 66] . As the disease progresses, defective efferocytosis and the ensuing accumulation of apoptotic macrophages and VSMCs impede the resolution of inflammation and thus promote plaque necrosis and instability. The proapoptotic effect of oxLDL on M2 macrophages may contribute to defective efferocytosis [67] .
The impact of macrophage apoptosis on atherosclerosis at early and advanced stages of plaque progression has been investigated using several genetically engineered mouse models ( Table 2) . Studies on the role of the growth suppressor and proapoptotic protein p53 have been discussed above. In Ldlr-KO mice, reconstitution with bone marrow from mice lacking the proapoptotic protein Bax reduces macrophage apoptosis and increases the size of aortic root lesions [68] . Similarly, increased aortic atherosclerosis in apoE-KO mice lacking p19 Arf is associated with attenuated macrophage and VSMC apoptosis, whereas intimal cell proliferation is unaffected [31 & ]. Conversely, inactivation of the prosurvival protein AIM (Spa/Api6) in Ldlr-KO mice increases macrophage apoptosis and inhibits atherosclerosis [69] . A similar coincidence of increased intimal apoptosis with reduced aortic atherosclerosis is seen in Ldlr-KO mice transplanted with fetal liver cells lacking EP4, the prostaglandin E(2) receptor involved in macrophage survival [70] . Moreover, intimal macrophage apoptosis induced in hypercholesterolemic rabbits by treatment with the nitro-oxide precursor L-arginine is accompanied by regression of pre-established atherosclerotic lesions [75] . Remarkably, using a number of approaches to manipulate macrophage apoptosis in apoE-KO mice, Gautier et al. [76] demonstrated that macrophage apoptosis is antiatherogenic during the early stages of atherosclerosis, but accelerates plaque progression in more advanced lesions.
Endoplasmic reticulum stress and macrophage apoptosis
Macrophage apoptosis is thought to promote the formation of the necrotic core in advanced atheromas, thus increasing plaque vulnerability and the risk of thrombotic vascular disease [77] . However, the underlying cellular and molecular mechanisms remain poorly characterized. Endoplasmic reticulum stress (ERS) has emerged as a general mediator of vascular inflammation and endothelial dysfunction in atherosclerosis that contributes to plaque vulnerability through the induction of macrophage and VSMC apoptosis [78, 79] . Signals that can lead to ERS and apoptosis in macrophages include the excessive accumulation of modified LDLs, which dysregulates calcium homeostasis and activates the mitochondrial apoptotic pathway, and palmitic acid, which up-regulates oxidized LDL receptor-1 (LOX-1) and enhances oxLDL uptake [80 & ,81 ,82] (Fig. 2) . Alleviation of ERS with the chemical chaperone 4-phenyl butyric acid results in marked protection against lipotoxic death in macrophages and reduces atherosclerosis in apoE-KO mice [71 && ]. Prolonged ERS induces inflammation in macrophages and activates several ERS-related proteins, including activating transcription factor-6 (ATF-6), inositol requiring protein-1 (IRE-1) and protein kinase RNA-like kinase (PERK) [83, 84] . Signaling pathways activated by these proteins cause the accumulation of unfolded proteins in the endoplasmic reticulum, which initiates the unfolded protein response (UPR) to restore normal endoplasmic reticulum function [85, 86] . However, if the stress is prolonged, or the adaptive response fails, apoptotic cell death ensues. A key effector of UPR-dependent apoptosis is the transcription factor CHOP (GADD153), which causes calcium release from the endoplasmic reticulum lumen to the mitochondria and the release of proapoptotic caspases [87] . CHOP also activates calcium/calmodulindependent protein kinase II (CaMKII), which in turn promotes cell death by activating both the extrinsic (death receptor/Fas) and the intrinsic (mitochondria/caspases) apoptosis pathways [88 & ]. Remarkably, fat-fed apoE-KO and Ldlr-KO mice lacking CHOP exhibit reduced lesional apoptosis and plaque necrosis and smaller atherosclerotic lesions [72 && ]. Apoptosis of endoplasmic reticulum-stressed macrophages in advanced atheromas appears to be triggered by cooperation between macrophage pattern recognition receptors (PRRs), such as A-type scavenger receptor (SRA) and Toll-like receptor 4 (TLR4), through a process involving signal transducer and activator of transcription-1 (STAT1), CaMKII and cytosolic calcium [73, 86, 89] . Macrophage apoptosis and plaque necrosis are decreased FIGURE 2 . Apoptosis of ER-stressed macrophages in advanced atheromas. Excessive accumulation of oxLDL up-regulates LOX-1, which in turn enhances oxLDL uptake and provokes ERS. Prolonged ERS activates ER-related proteins such as ATF-6, IRE-1 and PERK, which initiate the UPR. A key effector of UPR is the transcription factor CHOP, which causes the release of calcium and proapoptotic caspases from the ER. CHOP also activates CaMKII, which also promotes apoptosis by triggering the extrinsic (death receptor/Fas) and the intrinsic (mitochondria/caspases) apoptosis pathways. Apoptosis of ER-stressed macrophages in advanced atheromas appears to need a 'second hit' induced by PRRs, such as SRA and TLR4, through a process involving STAT1 and CaMKII. ATF-6, transcription factor-6; CaMKII, calcium/calmodulin-dependent protein kinase II; CHOP, CCAAT/enhancer-binding protein homologous protein; ERS, endoplasmic reticulum stress; IRE-1, inositol requiring protein-1; LOX-1, oxidized LDL receptor-1; oxLDLs, oxidized LDLs; PERK, protein kinase RNA-like kinase; PRRs, pattern recognition receptors; SRA, A-type scavenger receptor; STAT1, activator of transcription-1; TLR4, Toll-like receptor 4.
local inflammation and lesion growth by preventing secondary cellular necrosis. However, phagocytosis by lesional macrophages of lipoproteins, unwanted or dead cells and cellular debris also has strong proatherogenic effects that contribute to plaque destabilization and rupture. It is therefore unclear whether more benefit would be achieved by promotion of macrophage accumulation or by their removal from the atherosclerotic plaque. Mouse studies suggest that correct coupling of macrophage apoptosis and efferocytosis in early atherosclerosis limits atherosclerosis burden, whereas intimal macrophage and VSMC apoptosis and defective efferocytosis might promote necrosis in advanced lesions. Clearly, more research is needed to conclusively determine whether manipulation of proliferation and apoptosis in lesional macrophages has therapeutic potential. Further insight into these important processes will require a more complete understanding of the molecular and cellular mechanisms that regulate macrophage growth and apoptosis in atherosclerotic lesions. Achievement of this will require the generation of new mouse models with inducible macrophage-specific gene alterations to achieve gain or loss of function in specific phases of atherosclerosis. Work has begun on the pharmacological manipulation of these pathways to provide novel treatments for inflammatory disorders [90, 91] , and new advances in basic and preclinical research may translate into innovative therapies to combat atherothrombosis. In addition, because macrophage apoptosis is an important feature of advanced atherosclerotic plaques with a major impact on plaque stability, an increasing number of studies are attempting to identify macrophage apoptotic proteins as markers of plaque vulnerability [92, 93] .
Acknowledgements
We are grateful to Simon Bartlett for their English editing and María J. Andre´s-Manzano for help in preparing the figures. 
Conflicts of interest

REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 495-496).
